May 16, 2024 – Page 8 – Goldea Capital

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

Written by Customer Service on May 16, 2024. Posted in Earnings Releases And Operating Results.

Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan for Geographic Atrophy Implementation of Restructuring Plan to Reduce Operating Costs Existing Investors Support the Company with Issuance of $1 million in Unsecured Convertible Notes BOSTON and LONDON, May 16, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the first quarter ended March 31, 2024 as well as recent company highlights. “My first few weeks as Interim CEO of Akari have been filled with non-stop activity and...

HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter

Written by Customer Service on May 16, 2024. Posted in Earnings Releases And Operating Results.

NAPLES, Fla., May 16, 2024 (GLOBE NEWSWIRE) — via IBN — HealthLynked Corp. (OTCQB: HLYK), a leading provider of healthcare networking and technological innovation, has reported its financial results for the first quarter ending March 31, 2024. Demonstrating significant progress in streamlining its operating structure, HealthLynked achieved an 8% increase in revenue compared to the fourth quarter of 2023, showcasing consistent quarter-over-quarter growth and efficiency. First Quarter 2024 Financial Highlights: Revenue: Despite a 43% year-over-year decline due to changes in clinical staffing (one physician retired, another due to illness, and the third moved out of the area), HealthLynked’s revenue reached $1.00 million for the first quarter. The 8% quarter-over-quarter increase underscores the company’s resilience...

Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update

Written by Customer Service on May 16, 2024. Posted in Earnings Releases And Operating Results.

Twelve-month primary analysis results by independent central review from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) in anti-PD1 failed melanoma expected Q2 2024 Recent Type C CMC meeting with the U.S. Food and Drug Administration (FDA) supports IGNYTE Biologics License Application (BLA) submission expected in 2H 2024 Enrollment of first patients in Phase 3 confirmatory trial of RP1 in advanced melanoma expected in 2H 2024 Cash runway to fund operations into 2H 2026 WOBURN, Mass., May 16, 2024 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2024 and provided a business update. “We have exciting milestones...

Blackboxstocks Files Form S-4 for Evtec Acquisition

Written by Customer Service on May 16, 2024. Posted in Earnings Releases And Operating Results.

Reports First Quarter Financial Results for Fintech Operations DALLAS, May 16, 2024 (GLOBE NEWSWIRE) — Blackboxstocks Inc. (NASDAQ: BLBX), (“Blackbox” or the “Company”), a financial technology and social media hybrid platform offering real-time proprietary analytics for stock and options traders of all levels, announced that it filed its Form S-4 on May 13, 2024, for its acquisition of Evtec Aluminium Ltd. and today reported its financial results for the first quarter ended March 31, 2024. The filing of the S-4 was a significant milestone in the Company’s planned acquisition of Evtec Aluminium Ltd. Pending SEC and Nasdaq approval, the Company expects to consummate the merger as soon as possible. First Quarter Financial and Operating Highlights: Total revenue for the first quarter of 2024 was $649,420 as compared to $859,004 for...

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)

Written by Customer Service on May 16, 2024. Posted in Public Companies.

Topline results of the Phase 1b/2a clinical trial anticipated mid-year 2024 MIAMI, May 16, 2024 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the completion of the last patient’s final visit in the Company’s Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (“SBMA”), also known as Kennedy’s Disease. Topline data are expected to be reported mid-year 2024. “We are very excited to announce the last patient visit in the Phase 1b/2a clinical trial of AJ201 in SBMA, the final milestone before the anticipated topline data are reported in the middle of this year,” said Alexandra MacLean, M.D.,...

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

Written by Customer Service on May 16, 2024. Posted in Public Companies.

Fort Lee, NJ, May 16, 2024 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 2nd BioConnect Investor Conference at the NASDAQ world headquarters in New York City. Event H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ Date May 20th, 2024 Time 12:00 PM Eastern Time Link Fireside Chat [Link] About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment...

May 2024 Letter to Shareholders

Written by Customer Service on May 16, 2024. Posted in Public Companies.

VANCOUVER, Washington, May 16, 2024 (GLOBE NEWSWIRE) — Dear Shareholders, I write today to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), as we approach the end of our 2024 fiscal year (May 31, 2024), and to sincerely thank you for your unwavering support. Fiscal year 2024 was a significant year for CytoDyn, and one that I believe will be remembered as the beginning of a turnaround. The Company achieved the lifting of the FDA’s clinical hold in late February 2024 and is now working to return to the clinic. Over the past several months, the Company has made significant internal progress on key initiatives which we believe will lead to marked external developments in the form of the commencement of clinical trials, the rollout of a number of pre-clinical research initiatives, and the continued publication of leronlimab...

SHARC Energy Announces Q1 2024 Financial Results

Written by Customer Service on May 16, 2024. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia, May 16, 2024 (GLOBE NEWSWIRE) — SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) (“SHARC Energy” or the “Company”) announces it has filed financial results for the three months ended March 31, 2024. All figures are in Canadian Dollars and in accordance with IFRS unless otherwise stated. First Quarter Financial Highlights: As of May 16, 2024, the Company has a Sales Pipeline1 of $17.0 million (M) and Sales Order Backlog2 of $2.3M. Sales Pipeline saw a marginal increase of 1% or $0.1M while revenue recognition improved, drawing down Sales Order Backlog by $0.7M since April 29, 2024 disclosure. The Company has hit an inflection point in the maturity of its Sales Pipeline, giving management confidence that 2024 will be a transformative year for SHARC Energy. Revenue...

Imperial Petroleum Inc. Reports First Quarter 2024 Financial and Operating Results

Written by Customer Service on May 16, 2024. Posted in Earnings Releases And Operating Results.

ATHENS, Greece, May 16, 2024 (GLOBE NEWSWIRE) — IMPERIAL PETROLEUM INC. (NASDAQ: IMPP, the “Company”), a ship-owning company providing petroleum products, crude oil and drybulk seaborne transportation services, announced today its unaudited financial and operating results for the three months ended March 31, 2024. OPERATIONAL AND FINANCIAL HIGHLIGHTS Fleet operational utilization of 80.6% in Q1 24’, an improved performance compared to Q4 23’, mainly due to a 29.3% (65 days) decrease in commercial idle days. In Q1 23’our operational utilization was 85.0%. 75.0% of fleet calendar days, equivalent to 671 days, in Q1 24’ were dedicated to spot activity. Revenues of $41.2 million in Q1 24’, compared to $29.9 million in Q4 23’, equivalent to a 37.8% rise and $65.4 million of revenues in Q1 23’. Net Income of $16.7 million in Q1 24’...

Blockchain as a Service Market to Surpass USD 94.43 Billion by 2031 | SkyQuest Technology

Written by Customer Service on May 16, 2024. Posted in Mergers And Acquisitions.

Westford, USA, May 16, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that Global Blockchain as a Service Market will attain a value of USD 94.43 Billion by 2031, with a CAGR of 57.10% during the forecast period (2024-2031). Blockchain-as-a-service, or BaaS, refers to the use of third parties to build and manage cloud-based networks for businesses that create blockchain applications. In the quickly developing field of blockchain technology, third-party services are a relatively new concept. Blockchain technology is increasingly being used for safe transactions of many kinds, far beyond its most well-known application in bitcoin transactions. Throughout the projection period, the rise in cyberthreats following the COVID-19 pandemic contributed to the expansion of worldwide blockchain as a service (BaaS) solution. Download a detailed...

Day: May 16, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice